Gastrointestinal Endoscopy Device MarketSize, Share & Industry Analysis, 2026-2034By ProductBy Sales ChannelBy End UserBy UsageBy Application

Gastrointestinal endoscopy devices are the videoscopes, imaging processors, biopsy and resection instruments, hemostasis tools and accessory devices used to visualize, diagnose and treat conditions of the esophagus, stomach, small bowel, colon and pancreatobiliary tract. The category spans reusable and single-use scopes, capsule-based imaging systems and the retrieval, sampling and closure instruments used alongside them during a procedure. Buyers are hospital gastroenterology and endoscopy departments, ambulatory surgical centers and specialty clinics that perform diagnostic screening and therapeutic interventional procedures.

Growth of 7.3% a year carries the global gastrointestinal endoscopy device market from USD 54.2 billion in 2025 to USD 103.03 billion in 2034. The full series behind that rate covers USD 32 billion in 2020, USD 50.9 billion in 2024, USD 58.65 billion in 2026 and USD 78.9 billion in 2030, with 2025 as the base year.

31.99% of 2025 revenue sits in GI Videoscopes, worth USD 17.34 billion and rising to USD 29.9 billion at 29.02% by 2034, the largest product line in both years. Growth is fastest in Capsule Endoscopy at 10.2% and slowest in Hemostasis Devices at 5.42%. The lines gaining share are Capsule Endoscopy, Endoscopic Ultrasound and Endoscopic Mucosal Resection (EMR). GI Videoscopes, Biopsy Devices, Endoscopic Retrograde Cholangiopancreatography Devices (ERCP), Hemostasis Devices and Other Product Types lose share without losing revenue.

The sales channel split puts Medical Stores & Brand Outlet first, at USD 44.44 billion and 81.99% of revenue in 2025, rising to USD 78.3 billion and 76% in 2034. Online Retailing grows faster at 10.88% against 6.5%, moving from 18.01% of revenue to 24% by 2034. It cuts the same total as the product axis from a different commercial angle, so revenue does not add across the two.

North America is the largest region at 36.5% of 2025 revenue, worth USD 19.79 billion and reaching USD 34 billion by 2034. Asia Pacific follows at 27%, moving from USD 14.63 billion to USD 33.48 billion, and Middle East and Africa is the smallest at 5.2%. Share shifts toward Asia Pacific over the forecast period, which is what makes the regional split worth reading rather than assuming.

Coverage extends to five regions, eight product lines and five segmentation axes over the full fifteen years. The 2025 total itself is triangulated from published sources and category proxies rather than an independently sourced count, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.

• Revenue grows from USD 54.2 billion in 2025 to USD 103.03 billion in 2034, a compound annual rate of 7.3%, having reached USD 50.9 billion in 2024 from USD 32 billion in 2020.
• 31.99% of 2025 revenue sits in GI Videoscopes (USD 17.34 billion) and it remains the largest product line in 2034 at USD 29.9 billion and 29.02%.
• Capsule Endoscopy is the fastest-growing line at 10.2%, lifting its share from 11% in 2025 to 14% in 2034 and its revenue from USD 5.96 billion to USD 14.42 billion.
• Against a base case of USD 103.03 billion in 2034, the study also reports a bear case at USD 91.7 billion and a bull case at USD 118.48 billion, with the assumptions behind each set out separately.
• North America holds 36.5% of global revenue in 2025 at USD 19.79 billion, the largest of the five regions tracked, and reaches USD 34 billion by 2034.
• Within North America, the United States is the worked country example, at USD 17.42 billion in 2025; 88% of regional revenue in the base year, and USD 29.58 billion by 2034.
• Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region rather than a single blended series.

Three movements define the forecast period in the global gastrointestinal endoscopy device market: how the product mix changes, where regional weight shifts, and the rate at which the total compounds.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

Capsule Endoscopy outpaces Hemostasis Devices. 10.2% against 5.42%: that gap, between Capsule Endoscopy and Hemostasis Devices, is the largest on the product axis. Shares follow: 11% to 14% for Capsule Endoscopy, 6.99% to 6% for Hemostasis Devices. Revenue rises on both sides; USD 5.96 billion to USD 14.42 billion and USD 3.79 billion to USD 6.18 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.

Asia Pacific gain regional share. Asia Pacific moves from 27% of revenue in 2025 to 32.5% in 2034, worth USD 14.63 billion rising to USD 33.48 billion. Against that, North America at 36.5% moving to 33%, Europe at 25.5% moving to 24%, Latin America at 5.8% moving to 5.8%, Middle East and Africa at 5.2% moving to 4.7%, a fall in share, not in revenue. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.

A continuation, not an inflection. Year by year the total runs USD 32 billion in 2020, USD 50.9 billion in 2024, USD 54.2 billion in 2025, USD 58.65 billion in 2026, USD 78.9 billion in 2030 and USD 103.03 billion in 2034. The forecast rate of 7.3% sits against 11.11% over the historical period, so the projection extends an observed trend instead of proposing a new one. That moves the planning question away from timing a turn and onto the product and regional mixes, where the actual movement is.

Capsule Endoscopy adds the most incremental growth

Growth in the global gastrointestinal endoscopy device market comes from three measurable sources over 2026-2034: the market's own compounding at 7.3%, the share gained by faster-growing product lines, and expansion in the regions taking a larger part of global revenue.

What holds the forecast back

Where the forecast could be beaten

The total depends on a single line

North America holds 36.5% of the global gastrointestinal endoscopy device market in 2025, worth USD 19.79 billion rising to USD 34 billion in 2034. Among the five regions it ranks first by revenue in both years.

Share settles at 33% in 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight rather than as falling revenue.

Within the region the product split tracks the global one; 31.99% of 2025 revenue in GI Videoscopes, fastest growth of 10.2% in Capsule Endoscopy. Revenue for North America is broken out by every segmentation axis and by country in the full report.

88% of North America's base-year revenue comes from the United States; USD 17.42 billion, rising to USD 29.58 billion by 2034. At 88% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. The region itself runs USD 19.79 billion to USD 34 billion over the same period, and this is the market carrying the country-level detail in the full report.

the United States buys along the same lines as the market globally; GI Videoscopes first at 31.99% of 2025 revenue and 29.02% in 2034, Capsule Endoscopy fastest at 10.2% on a share moving from 11% to 14%. Its 88% weight in North America means those movements carry straight into the regional totals. Revenue by product for the United States is reported separately in the full report.

In the United States, gastrointestinal endoscopy devices are regulated by the Food and Drug Administration as medical devices, with most flexible and rigid endoscopes and their reusable accessories classified in the moderate-risk category that requires a premarket notification demonstrating substantial equivalence to a legally marketed predicate device before commercial distribution. Manufacturers must operate under the FDA's quality system requirements covering design controls, manufacturing, and complaint handling, and must comply with labeling rules addressing intended use, reprocessing instructions, and warnings. Devices intended for repeated use are additionally expected to demonstrate validated cleaning, disinfection, and sterilization protocols consistent with recognized voluntary consensus standards referenced by the agency.

In the United States the field is Boston Scientific, Medtronic, Fujifilm Holdings Corporation, CONMED Corporation, Stryker Corporation, Johnson & Johnson, Olympus, Cook Group, Becton, Dickinson, B. Braun Melsungen, Karl Storz SE & Co. KG, HOYA Corporation (Pentax Medical), STERIS plc, Ambu A/S and Erbe Elektromedizin GmbH. Volume sits in GI Videoscopes at 31.99% of 2025 revenue; movement sits in Capsule Endoscopy at 10.2% growth. Per-company positioning and share at country level are in the full report only.

4.37% of global revenue is generated in Canada; USD 2.37 billion in 2025, reaching USD 4.42 billion in 2034, and 11.98% of North America.

In Europe, 25.5% of global revenue puts 2025 at USD 13.82 billion with USD 24.73 billion projected for 2034. That makes it the third-largest region covered, in 2025 and again in 2034.

Its share moves to 24% by 2034, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.

Within the region the product split tracks the global one; 31.99% of 2025 revenue in GI Videoscopes, fastest growth of 10.2% in Capsule Endoscopy. Revenue for Europe is broken out by every segmentation axis and by country in the full report.

USD 4.15 billion of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 7.17 billion by 2034. At 30% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. The region itself runs USD 13.82 billion to USD 24.73 billion over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is GI Videoscopes at 31.99% of 2025 revenue, easing to 29.02% by 2034, and the fastest is Capsule Endoscopy at 10.2%, from 11% to 14%. Because the country carries 30% of Europe, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. Revenue by product for Germany is reported separately in the full report.

In Germany, gastrointestinal endoscopy devices fall under the European Union's Medical Device Regulation, administered domestically through the competent authority BfArM alongside independent Notified Bodies that assess conformity. Most endoscopes and reusable accessories are classified as medium-risk devices requiring a Notified Body-audited conformity assessment before a manufacturer may affix the CE mark and place the product on the market. Suppliers must maintain technical documentation, a post-market surveillance system, and clinical evaluation evidence, and must meet harmonized standards covering biocompatibility, electrical safety, and reprocessing validation. Labelling must be provided in German and include intended purpose, handling, and sterilization or disinfection instructions.

In Germany the field is Boston Scientific, Medtronic, Fujifilm Holdings Corporation, CONMED Corporation, Stryker Corporation, Johnson & Johnson, Olympus, Cook Group, Becton, Dickinson, B. Braun Melsungen, Karl Storz SE & Co. KG, HOYA Corporation (Pentax Medical), STERIS plc, Ambu A/S and Erbe Elektromedizin GmbH. Volume sits in GI Videoscopes at 31.99% of 2025 revenue; movement sits in Capsule Endoscopy at 10.2% growth.

5.61% of global revenue is generated in the United Kingdom; USD 3.04 billion in 2025, reaching USD 5.19 billion in 2034, and 22% of Europe.

4.59% of global revenue is generated in France; USD 2.49 billion in 2025, reaching USD 4.2 billion in 2034, and 18% of Europe.

In Asia Pacific, 27% of global revenue puts 2025 at USD 14.63 billion with USD 33.48 billion projected for 2034. That makes it the second-largest region covered, in 2025 and again in 2034.

Share climbs to 32.5% by 2034, because it outgrows the market's 7.3%; the revenue added here is disproportionate to where the region started.

The product mix reported at global level applies here, with GI Videoscopes the largest line at 31.99% of 2025 revenue and Capsule Endoscopy the fastest-growing at 10.2%. Per-axis and per-country detail for Asia Pacific sits in the full report.

USD 4.97 billion of Asia Pacific's 2025 revenue is generated in China, the region's largest market, reaching USD 12.05 billion by 2034. Its 34% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Set against USD 14.63 billion and USD 33.48 billion for the region, it is why this market rather than a smaller one is the one reported in full.

Composition here matches the global split: the largest line is GI Videoscopes at 31.99% of 2025 revenue, easing to 29.02% by 2034, and the fastest is Capsule Endoscopy at 10.2%, from 11% to 14%. With 34% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. China carries its own product breakdown in the full report.

In China, gastrointestinal endoscopy devices are regulated by the National Medical Products Administration, which classifies them according to risk, with most endoscopes and their reusable accessories treated as higher-risk devices requiring formal registration rather than simple filing. Registration requires clinical evaluation or clinical trial data, a quality management system audit, and testing against applicable national standards covering safety, performance, and biocompatibility. Imported devices additionally require a local agent and must pass customs and inspection requirements before distribution. Labelling and instructions for use must appear in Chinese and specify intended use, contraindications, and validated reprocessing procedures for reusable components.

In China the field is Boston Scientific, Medtronic, Fujifilm Holdings Corporation, CONMED Corporation, Stryker Corporation, Johnson & Johnson, Olympus, Cook Group, Becton, Dickinson, B. Braun Melsungen, Karl Storz SE & Co. KG, HOYA Corporation (Pentax Medical), STERIS plc, Ambu A/S and Erbe Elektromedizin GmbH. Two different problems sit on the same axis: holding GI Videoscopes at 31.99% of 2025 revenue, and taking Capsule Endoscopy while it grows at 10.2%.

Within Asia Pacific, Japan accounts for 26% of regional revenue and 7.01% of the global total, worth USD 3.8 billion in 2025 and USD 7.37 billion by 2034.

Within Asia Pacific, India accounts for 14% of regional revenue and 3.78% of the global total, worth USD 2.05 billion in 2025 and USD 5.69 billion by 2034.

USD 3.14 billion of 2025 revenue is generated in Latin America, 5.8% of the global gastrointestinal endoscopy device market rising to USD 5.98 billion in 2034. Among the five regions it ranks fourth by revenue in both years.

By 2034 the share stands at 5.8%, a shift in share rather than in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Within the region the product split tracks the global one; 31.99% of 2025 revenue in GI Videoscopes, fastest growth of 10.2% in Capsule Endoscopy. Revenue for Latin America is broken out by every segmentation axis and by country in the full report.

Brazil is the largest market within Latin America, generating USD 1.63 billion in 2025 and projected to reach USD 3.05 billion by 2034. At 51.9% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. The region itself runs USD 3.14 billion to USD 5.98 billion over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is GI Videoscopes at 31.99% of 2025 revenue, easing to 29.02% by 2034, and the fastest is Capsule Endoscopy at 10.2%, from 11% to 14%. Its 51.9% weight in Latin America means those movements carry straight into the regional totals. Per-product revenue for Brazil appears on its own in the full report.

In Brazil, gastrointestinal endoscopy devices are regulated by the National Health Surveillance Agency, ANVISA, which classifies medical devices by risk and requires either registration or a simpler notification depending on that classification, with most endoscopes and reusable accessories subject to full registration given their invasive, reusable nature. Manufacturers and importers must hold a valid operating authorization, demonstrate compliance with Brazilian good manufacturing practice requirements, and in many cases undergo facility certification. Labelling must be in Portuguese and include intended use, handling, and reprocessing instructions, and reusable components must show validated cleaning and sterilization protocols aligned with recognized standards before sale is permitted.

In Brazil the field is Boston Scientific, Medtronic, Fujifilm Holdings Corporation, CONMED Corporation, Stryker Corporation, Johnson & Johnson, Olympus, Cook Group, Becton, Dickinson, B. Braun Melsungen, Karl Storz SE & Co. KG, HOYA Corporation (Pentax Medical), STERIS plc, Ambu A/S and Erbe Elektromedizin GmbH. Volume sits in GI Videoscopes at 31.99% of 2025 revenue; movement sits in Capsule Endoscopy at 10.2% growth.

Mexico is sized at USD 0.88 billion in 2025, rising to USD 1.73 billion by 2034; 1.62% of global revenue and 28% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

Middle East and Africa holds 5.2% of the global gastrointestinal endoscopy device market in 2025, worth USD 2.82 billion rising to USD 4.84 billion in 2034. Among the five regions it ranks fifth by revenue in both years.

4.7% of global revenue sits here in 2034, below the 2025 level, a shift in share rather than in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

The product mix reported at global level applies here, with GI Videoscopes the largest line at 31.99% of 2025 revenue and Capsule Endoscopy the fastest-growing at 10.2%. Middle East and Africa is reported axis by axis and country by country in the full study.

30.1% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 0.85 billion, rising to USD 1.5 billion by 2034. 30.1% of the region in the base year makes it the largest market here without making it the region. Set against USD 2.82 billion and USD 4.84 billion for the region, it is why this market rather than a smaller one is the one reported in full.

Saudi Arabia buys along the same lines as the market globally; GI Videoscopes first at 31.99% of 2025 revenue and 29.02% in 2034, Capsule Endoscopy fastest at 10.2% on a share moving from 11% to 14%. Its 30.1% weight in Middle East and Africa means those movements carry straight into the regional totals. Revenue by product for Saudi Arabia is reported separately in the full report.

In Saudi Arabia, gastrointestinal endoscopy devices are regulated by the Saudi Food and Drug Authority under its medical device framework, which follows a risk-based classification broadly aligned with international harmonization guidance. Suppliers must obtain marketing authorization through the authority's medical device registration system before a product may be sold, supported by evidence of conformity to recognized international standards, a valid quality management system certification, and appointment of an authorized local representative. Labelling must be provided in Arabic alongside English and must state intended use, handling precautions, and instructions for reprocessing where the device or its accessories are intended for repeated use.

In Saudi Arabia the field is Boston Scientific, Medtronic, Fujifilm Holdings Corporation, CONMED Corporation, Stryker Corporation, Johnson & Johnson, Olympus, Cook Group, Becton, Dickinson, B. Braun Melsungen, Karl Storz SE & Co. KG, HOYA Corporation (Pentax Medical), STERIS plc, Ambu A/S and Erbe Elektromedizin GmbH. GI Videoscopes, at 31.99% of 2025 revenue, is where the volume sits, and Capsule Endoscopy, growing at 10.2%, is where position changes hands over the forecast period.

1.14% of global revenue is generated in South Africa; USD 0.62 billion in 2025, reaching USD 1.02 billion in 2034, and 22% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Product, Sales Channel, End User, Usage, Application, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.